Ignite Creation Date:
2025-12-24 @ 7:16 PM
Ignite Modification Date:
2026-01-05 @ 5:28 PM
Study NCT ID:
NCT03139903
Status:
COMPLETED
Last Update Posted:
2017-11-20
First Post:
2017-03-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Primordial Dwarfisms: Diagnosis, Identification of the Molecular Basis of Seckel Syndrome and Microcephalic Osteodysplastic Primordial Dwarfism Type II
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Study Overview
Official Title:
The Primordial Dwarfisms: Diagnosis, Identification of the Molecular Basis of Seckel Syndrome and Microcephalic Osteodysplastic Primordial Dwarfism Type II (MOPDII).
Status:
COMPLETED
Status Verified Date:
2017-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
NANPIM
Brief Summary:
The purpose of this study si to define morphological and epidemiological parameters and identify new symptoms in French patients with Seckel syndrome (SCKL) or microcephalic osteodysplastic primordial dwarfism type II (MOPDII).
Detailed Description:
Multicentre study, aiming to determine morphological and epidemiological parameters and identify new symptoms in French patients with SCKL or MOPDII.
At pre-inclusion visit: Realization of the photographs of: the face, entire body and the extremities (hands and feet) that will be serve for the collegiate decision of the inclusion or not of patients.
Patients are seen at inclusion V1 , a second visit V2 at 6-10 months after V1 and an annual follow-up visit.
At inclusion:
* Full Clinical Examination, specialized consultations (Otorhinolaryngology, stomatology, orthopedics, ophthalmology)
* Results of x-ray examinations and biological tests
* Assessment of the patients competencies and initiation of appropriate care ( orthophony and psychomotricity...)
* Assessment of intelligence and cognitive ability according the WISC-IV scale
* Blood testing for diagnosis and research.
Visit 2:
* Full Clinical Examination
* Cerebral angiography-MRI for all patients
* Programming a neurosurgery / neurovascular consultation based on MRI results
* Immuno-hematology and hepato-gastroenterology consultation if anomaly during the visit V1
Annual follow-up visit:
* Assessment of the complications of the disease and its clinical care
* Full clinical examination
* Skeletal x-ray and systematic orthopedic consultation
* Blood Check
* Prescription of tests if necessary depending to the complications identified of the disease
* Reevaluation of the care according to the detected symptoms
At pre-inclusion visit: Realization of the photographs of: the face, entire body and the extremities (hands and feet) that will be serve for the collegiate decision of the inclusion or not of patients.
Patients are seen at inclusion V1 , a second visit V2 at 6-10 months after V1 and an annual follow-up visit.
At inclusion:
* Full Clinical Examination, specialized consultations (Otorhinolaryngology, stomatology, orthopedics, ophthalmology)
* Results of x-ray examinations and biological tests
* Assessment of the patients competencies and initiation of appropriate care ( orthophony and psychomotricity...)
* Assessment of intelligence and cognitive ability according the WISC-IV scale
* Blood testing for diagnosis and research.
Visit 2:
* Full Clinical Examination
* Cerebral angiography-MRI for all patients
* Programming a neurosurgery / neurovascular consultation based on MRI results
* Immuno-hematology and hepato-gastroenterology consultation if anomaly during the visit V1
Annual follow-up visit:
* Assessment of the complications of the disease and its clinical care
* Full clinical examination
* Skeletal x-ray and systematic orthopedic consultation
* Blood Check
* Prescription of tests if necessary depending to the complications identified of the disease
* Reevaluation of the care according to the detected symptoms
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: